Victoza® (liraglutide 1.8 mg) Provided Superior HbA1c Reductions in Adults with Type 2 Diabetes Compared to Continued Sitagliptin Treatment

BOSTON, April 2, 2016 /PRNewswire/ --

For non-US medical media only.     

For journalistic assessment and preparation before publication.     

Abstract #689-P  

Findings from a clinical trial comparing Victoza(R) (liraglutide 1.8 mg) and sitagliptin (100 mg), both in combination with metformin, demonstrated that switching from sitagliptin to Victoza(R) provided superior HbA1c reductions vs continuing with sitagliptin treatment in adults with type 2 diabetes. Results from the LIRA-SWITCH trial were presented at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US.[1]

The 26-week LIRA-SWITCH trial assessed the efficacy and safety of Victoza(R) as an add-on to metformin in 407 adults with type 2 diabetes who switched from sitagliptin.[1] Of the 407 adults uncontrolled on sitagliptin (HbA1c 7.5-9.5%) at week 26, those who switched to Victoza(R) (n=203) achieved a superior reduction in HbA1c vs those who continued their sitagliptin treatment (n=204) (-1.14% vs -0.54%; estimated treatment difference [ETD] -0.61%, 95% confidence interval [CI]: -0.82 to -0.40, p

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen